A Randomized Phase II Trial of ASTX727 and Venetoclax Compared with ASTX727, Venetoclax, and Enasidenib for Newly Diagnosed Older Adults with IDH2 Mutant Acute Myeloid Leukemia: A MyeloMATCH Substudy
MM1OA-S03 is re-opened to accrual on February 23, 2026, effective 10:00 a.m. Pacific Time.
(See required screening study MYELOMATCH)
